ImmunityBio director awarded 65,600 stock options

ImmunityBio director Cheryl Cohen received a new stock option grant.

Rhea-AI Filing Summary

ImmunityBio director Cheryl Cohen received a new stock option grant. She was awarded options to buy 65,600 shares of ImmunityBio common stock at an exercise price of $7.25 per share, expiring on June 9, 2036. This is a compensation-related award, not an open-market purchase.

The option vests in full only if she continues as a service provider. All 65,600 shares underlying the award will vest on the earlier of June 9, 2027 or the date immediately before the next annual meeting of stockholders. Following this grant, she holds 65,600 stock options directly.

Insights

Equity compensation analyst

Routine equity grant gives director long-dated upside with no cash outlay yet.

The filing shows director Cheryl Cohen receiving a stock option covering 65,600 ImmunityBio shares at an exercise price of $7.25, expiring on June 9, 2036. This grant is classified as a compensation-related acquisition, not an open-market buy or sell.

The award uses a cliff-vesting structure: 100% vests on the earlier of June 9, 2027 or the day before the next annual stockholder meeting, assuming she remains a service provider. Until vesting and exercise, there is no cash paid to the company and no share issuance.

Because this is a standard director equity grant with no associated sale and no large change in ownership, it is best viewed as routine governance practice rather than a directional signal about the company’s near-term prospects.

Insider Trade Summary

Grant/Award: 65,600 shares

Grant/Award 1 txn

Insider Cohen Cheryl

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	65,600	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 65,600 contracts (Direct)

Footnotes (1)

1. F1. Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders.

Key Figures

Option size: 65,600 shares Exercise price: $7.25 per share Expiration date: June 9, 2036 +2 more

5 metrics

Option size 65,600 shares Stock option grant underlying common stock

Exercise price $7.25 per share Stock option strike price

Expiration date June 9, 2036 Option term end date

Post-transaction options held 65,600 shares Total derivative holdings following grant

Vesting date Earlier of June 9, 2027 or pre-next annual meeting Cliff vesting condition if service continues

Key Terms

Stock Option, exercise price, Equity Incentive Plan, vesting

4 terms

Stock Option financial

"Stock Option (right to buy)"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"conversion_or_exercise_price": "7.2500""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Equity Incentive Plan financial

"defined in the Issuer's 2025 Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

vesting financial

"the shares subject to the award will vest on the earlier"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ImmunityBio (IBRX) director Cheryl Cohen report on this Form 4?

Cheryl Cohen reported receiving a stock option grant for 65,600 shares of ImmunityBio common stock. The option has an exercise price of $7.25 per share and is structured as a compensation-related award, not an open-market purchase or sale of existing shares.

What are the key terms of Cheryl Cohen’s new ImmunityBio (IBRX) stock option?

The option covers 65,600 ImmunityBio common shares at a $7.25 exercise price and expires June 9, 2036. It vests in full only if service continues, on the earlier of June 9, 2027 or the date immediately before the next annual stockholder meeting.

Is Cheryl Cohen buying or selling ImmunityBio (IBRX) shares in this Form 4?

She is not buying or selling shares on the market. The Form 4 shows a grant of stock options as compensation, giving her the right to buy 65,600 shares at $7.25 in the future if she satisfies the vesting conditions and chooses to exercise.

How many ImmunityBio (IBRX) options does Cheryl Cohen hold after this transaction?

After this transaction, Cheryl Cohen is reported as directly holding stock options covering 65,600 shares of ImmunityBio common stock. This entire amount comes from the newly granted award disclosed in the Form 4, with no additional derivative positions listed in the filing.

When do Cheryl Cohen’s ImmunityBio (IBRX) options vest according to the filing?

All 65,600 option shares vest in a single tranche if she continues as a service provider. Vesting occurs on the earlier of June 9, 2027 or the date immediately preceding ImmunityBio’s next annual meeting of stockholders, as specified in the Form 4 footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/10/2026 - 08:11 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cohen Cheryl

(Last) (First) (Middle)

C/O IMMUNITYBIO, INC.

3530 JOHN HOPKINS COURT

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ImmunityBio, Inc. [ IBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.25	06/09/2026		A		65,600		(1)	06/09/2036	Common Stock	65,600	$0	65,600	D

Explanation of Responses:

1. Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders.

Remarks:

Exhibit 24 - Power of Attorney

	/a/ David C. Sachs, as Attorney-in-Fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)